Abstract

Chronic viral hepatitis is a global public health concern affecting millions of people worldwide. Traditional treatment options for chronic viral hepatitis, including interferon-based therapies, often had limited efficacy and significant side effects. However, the advent of direct acting antivirals (DAAs) has revolutionized the management of chronic viral hepatitis. In this comprehensive review, we provide an overview of the classes of DAAs available for the treatment of chronic hepatitis B and C, highlighting their mechanisms of action, clinical efficacy, safety profiles, and impact on viral clearance. Additionally, we discuss the challenges and future prospects of DAA therapy, emphasizing the potential for achieving sustained virologic responses and eventually eradicating chronic viral hepatitis.